Skip to main content
Premium Trial:

Request an Annual Quote

Don't Count Us Out Yet

Over at bbgm, Deepak Singh considers a slide that's been circulating which compares the number of approved New Molecular Entities to spending by members of PhRMA from 1970 to the early 2000s. Paul Kedrosky, who presented the slide recently, notes that "the mapping of the genome, and other such inflection points in this failure-prone industry, has done nothing to accelerate [new] drugs, while causing costs to escalate dramatically."

Singh takes him to task for the comment. "I’ve seen that argument made a lot and you can’t really deny that we haven’t had a lot of success to show for the progress we’ve made over the past decade, but I’d like to stress on that last bit, past decade. Genomics, etc are very new," he writes. "We’ve barely scratched the surface, and a real impact on drug development is still years away, especially if we are talking about NMEs."

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.